Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma
JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 16.11.2026
DOI: 10.1111/ddg.70543 ↗Kurz gefasst
Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 16.11.2026. Verfasst von Dongzhao Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital (Shenzhen People's Hospital), School of Medicine, Southern University of Science and Technol…. Die Arbeit nennt 17 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
To investigate the short‐term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima‐type palmoplantar keratoderma (NPPK).
Methods
A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12.
Results
The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction).
Conclusions
Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long‐term efficacy and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital (Shenzhen People's Hospital), School of Medicine, Southern University of Science and Technology, Shenzhen, China.
- Department of Rheumatology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
- Capital Medical University Beijing Hospital of Traditional Chinese Medicine, Beijing, China.
ORCID-Profile: Chen Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, D., Meng, F., Chen, Y., Lin, Z., & Li, C. (2026). Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.70543
Vancouver
Xu D, Meng F, Chen Y, Lin Z, Li C. Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.70543
BibTeX
@article{Xu2026,
author = {Xu, Dongzhao and Meng, Fanzhang and Chen, Yuan and Lin, Zhimin and Li, Chen},
title = {Short‐term efficacy of tofacitinib in the treatment of Nagashima‐type palmoplantar keratoderma},
journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
year = {2026},
doi = {10.1111/ddg.70543}
}
EUVIMED